Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche

Allogeneic, T_SCM-rich dual CAR-T for the treatment of hematologic malignancies, including multiple myeloma

Nomination triggers $15 million milestone payment to Poseida, extending cash runway into early 2026

Read more at prnewswire.com